Compugen Ltd. (NASDAQ: CGEN) announced today that Dr. Mary Haak-Frendscho, Compugen Inc.'s Executive Chairperson of the Board, will deliver the keynote address at the 7th International China Pharmaceutical R&D Summit, on April 24, 2012 in Shanghai, China. In her presentation, Compugen’s R&D Collaboration Model for Predictive Drug Discovery, Dr. Haak-Frendscho will introduce Compugen's unique in silico target discovery engine for predicting novel proteins and their function in disease modulation. She also will discuss the partnership model for translating those targets into first-in-class antibody drugs. About Compugen Inc. Located in South San Francisco, Compugen Inc., a wholly owned subsidiary of Compugen Ltd., is dedicated to the development of oncology and immunology monoclonal antibody (mAb) drug candidates for licensing and partnering based on the growing portfolio of novel mAb targets being discovered and validated by the parent company. About Compugen Ltd. Compugen Ltd. is a leading therapeutic product discovery company focused on therapeutic proteins and monoclonal antibodies to address important unmet needs in the fields of immunology and oncology, either for Compugen or its partners. Unlike traditional high throughput trial and error experimental based drug candidate discovery, Compugen's discovery efforts are based on systematic and continuously improving in silico (by computer) product candidate prediction and selection followed by experimental validation, with selected product candidates being advanced in its Pipeline Program to the pre-IND stage. Compugen's in silico predictive models utilize a broad and continuously growing infrastructure of proprietary scientific understandings and predictive platforms, algorithms, machine learning systems and other computational biology capabilities. The Company's business model primarily involves collaborations covering the further development and commercialization of Compugen-discovered product candidates and various forms of research and discovery agreements, in both cases providing Compugen with potential milestone payments and royalties on product sales or other forms of revenue sharing. In 2012, Compugen established operations in California for the development of oncology and immunology monoclonal antibody drug candidates against Compugen-discovered targets. In 2002, Compugen established an affiliate, Evogene Ltd. ( www.evogene.com) ( TASE: EVGN.TA), to utilize certain of the Company's in silico predictive discovery capabilities in agricultural biotechnology. For additional information, please visit Compugen's corporate website at www.cgen.com. This press release may contain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These statements include words such as “may”, “expects”, “anticipates”, “believes”, and “intends”, and describe opinions about future events. These forward-looking statements involve known and unknown risks and uncertainties that may cause the actual results, performance or achievements of Compugen to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. These and other factors are discussed in the "Risk Factors" section Compugen’s Annual Report on Form 20-F for the year ended December 31, 2011 as filed with the Securities and Exchange Commission. In addition, any forward-looking statements represent Compugen’s views only as of the date of this release and should not be relied upon as representing its views as of any subsequent date. Compugen does not assume any obligation to update any forward-looking statements unless required by law.